Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Berka – page 29

439 clinical trials in Bad Berka, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Berka at a glance
439
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

439 trials in Bad Berka

Open in trial search

Study on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Phenylbutyrate
  • Sponsor:Amylyx Pharmaceuticals Inc.

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Novartis Pharma AG

Migraine+1

Not recruiting

Study of Eptinezumab as Add-on Treatment for Prevention of Migraine in Adults with Both Migraine and Medication Overuse Headache

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Hypertension

Not recruiting

Study on Baxdrostat for Lowering Blood Pressure in Patients with Resistant Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Utreloxastat
  • Sponsor:PTC Therapeutics Inc.

Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Malignant melanoma+1

Not recruiting

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Berka

What the registry says about research in the country

01 Lung Cancer Research

Comprehensive studies focusing on various types of non-small cell lung cancer and small cell lung cancer, evaluating novel therapeutic approaches and combination treatments.

  • Advanced NSCLC Treatment
  • Extensive-Stage SCLC Therapy
  • Targeted Molecular Treatments

Multiple trials exploring immunotherapy combinations and targeted therapies for different lung cancer subtypes.

02 Pulmonary Fibrosis Studies

Innovative research examining treatments for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, with a focus on improving lung function and quality of life.

  • Novel Inhaled Therapies
  • Disease Progression Management
  • Long-term Treatment Options

Studies evaluating both established and experimental treatments for fibrotic lung conditions.

03 Neuroendocrine Research

Clinical investigations into neuroendocrine tumors, particularly focusing on gastroenteric and pancreatic origins, testing innovative therapeutic approaches.

  • Advanced NET Treatments
  • Targeted Therapies
  • Progressive Disease Management

Trials examining novel treatment combinations and targeted therapies for neuroendocrine neoplasms.

04 Cardiovascular Studies

Research focusing on managing hypercholesterolemia through innovative therapeutic approaches and long-term treatment strategies.

  • Cholesterol Management
  • Novel Drug Development
  • Treatment Effectiveness

Studies evaluating new medications and their impact on cholesterol levels and cardiovascular health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.